BMRN — BIOMARIN PHARMACEUTICAL INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1048477 ·
Last close
$60.02
Market Cap
$11.60B
52W High
$63.05
52W Low
$49.26
ADV30
1,828,340
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 766,208,000 | 571,209,000 | 129,630,000 | 105,527,000 | 8,591,016,000 | 2,222,435,000 | 2,378,909,000 |
| Dec 2025 | 874,565,000 | 598,856,000 | -44,603,000 | -46,573,000 | 7,594,022,000 | 1,311,679,000 | 1,507,023,000 |
| Sep 2025 | 776,133,000 | 636,048,000 | -46,677,000 | -30,744,000 | 7,614,868,000 | 1,250,108,000 | 1,558,157,000 |
| Jun 2025 | 825,410,000 | 675,320,000 | 276,866,000 | 240,532,000 | 7,456,341,000 | 1,213,816,000 | 1,429,228,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$874,251,000
Investing CF
$339,524,000
Financing CF
$809,552,000
CapEx
$-115,130,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$1.37
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$259,733,000
Inventory
$1,273,221,000
Receivables
$903,914,000
ST Investments
$0
EBIT TTM
$408,588,000
Pretax Income TTM
$385,594,000
Interest Exp TTM
$22,994,000
Analysts
24
Yahoo Snapshot (yfinance, live)
Total Revenue
$3,242,316,032
EBITDA
$631,289,024
Free Cash Flow
$459,422,496
Enterprise Value
$10,818,098,176
Total Cash
$2,222,435,072
Total Debt
$1,439,601,024
Shares Out
193,284,438
Trailing EPS
$1.39
Book Value
$32.14
ROE
4.5%
ROA
4.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 3,221,253,000 | 409,495,000 | 348,901,000 | 7,594,022,000 | 1,507,023,000 | — | 827,994,000 |
| Dec 2024 | 2,853,915,000 | 474,239,000 | 426,859,000 | 6,988,940,000 | 1,330,950,000 | — | 572,841,000 |
| Dec 2023 | 2,419,226,000 | 185,780,000 | 167,645,000 | 6,841,603,000 | 1,890,054,000 | — | 159,259,000 |
| Dec 2022 | 2,096,039,000 | 57,410,000 | 141,561,000 | 6,375,074,000 | 1,771,918,000 | — | 175,902,000 |
TTM Snapshot
Revenues TTM
$2,241,155,000
NetIncome TTM
$103,312,000
OpCashFlow TTM
$0
Assets (Latest)
$6,988,940,000
Forward EPS
$6.39
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ARWR | ARROWHEAD PHARMACEUTICALS, INC. | $11.92B | $84.65 | — |
| AXSM | Axsome Therapeutics, Inc. | $11.22B | $217.99 | — |
| AAVXF | Abivax S.A. | $12.12B | $139.00 | — |
| ABVX | Abivax S.A. | $10.89B | $124.92 | — |
| CORT | CORCEPT THERAPEUTICS INC | $12.38B | $114.49 | — |
News headlines (Yahoo Finance, 1h cache)
BioMarin to Host Second Quarter 2026 Financial Results Conference Call and Webcast on Thursday, August 6, 2026, at 4:30pm ET
2026-07-30 13:00 · Yahoo
Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy?
2026-07-28 14:00 · Yahoo
BioMarin and n-Lorem partner on early research for ReNU syndrome therapy
2026-07-28 10:30 · Yahoo
Analysts Estimate BioMarin Pharmaceutical (BMRN) to Report a Decline in Earnings: What to Look Out for
2026-07-27 14:00 · Yahoo
BioMarin and n-Lorem Foundation Enter Early Research Collaboration to Develop Potential First-in-Disease Medicine for Newly Identified ReNU Syndrome
2026-07-27 13:05 · Yahoo
2 Reasons to Avoid BMRN and 1 Stock to Buy Instead
2026-07-17 15:45 · Yahoo
Collect 9.8% On VRTX Stock Now, And Still Keep 15% Of Upside
2026-07-16 13:06 · Yahoo
FDA Accepts BMRN's sNDA Seeking Full Approval for Voxzogo
2026-07-14 14:42 · Yahoo
BioMarin Pharmaceutical (BMRN) Following Its VOXZOGO FDA Filing And The Case For Undervaluation
2026-07-13 22:16 · Yahoo
1 of Wall Street’s Favorite Stocks with Competitive Advantages and 2 We Avoid
2026-07-13 17:10 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.